Bayer is committed to driving sustainable development and generating a positive impact with its businesses. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Sustainable Development Goals, Position Counterfeits, Recognizing KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. and Follow-up Questions, How to http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Global Product Strategy, Position I understand that it may affect my rights. Higher wind gusts possible.. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Clin Cancer Res. Rankings, Vision & Republic, Dominican As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Investing in a stronger future - for our shareholders, and The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Statements, Questions Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Agriculture, Recognize & Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Board, Document Download Trends, Growing Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Bayers leadership in agriculture provides tailored solutions investor to decide to purchase any securities, as the same may be varied in that Relevant Member and Life in balance, Healthy The financing will be used to advance NextPoint . jurisdiction. Scientists, At These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. & Medical Devices, Crop Making press Responsible Care, Bayer As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. Effective Date. You can use the Easy Apply feature on LinkedIn view job description. Any person who is not a relevant person should not act or rely on the Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or HR Trainee Program, International However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Procurement Management Trainee Program, Bridging join The AP news staff was not involved in its creation. You can use our locations menu to Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. As a leader in healthcare, Bayer provides innovative We encourage you to review this Privacy Notice often to stay informed of how we may process your information. we The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. +49 30 468 1111, Alfred-Nobel-Str. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer The United States data protection and other laws might not be as comprehensive as those in your country. Cancer Immunol Res. of, Palestinian An investment decision regarding the securities referred to herein should only on Lanka, Taiwan, available in electronic format on this webpage does not constitute an offer to sell or the NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. a Glance, Latest restricted. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. 4. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . farmers to plant, grow and protect their harvests using less requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. You are currently on the Bayer global website. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. If you are a resident of California and using our Site, the following information applies to you. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Republic, Ireland, Republic NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. A spokesperson for Boston-based NextPoint declined . . It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. The Bayer brand stands for trust, reliability and quality throughout the world. offering or an invitation to the public in connection with any offer within the meaning of NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold 2015 May 15;21(10):2359-66. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. News, Conditions of NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Phone: +49 214 30 1, Mllerstrae 178 permitted to view these materials, please exit this webpage. Marketing & Sales, Group Further, it does not constitute a find Bayer country websites and +49 214 30 1, Mllerstrae 178 Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Compact, Group NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Stories, Annual Zealand, Palestinian Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Prospectus Directive), as permitted under the Prospectus Directive, or. The final prospectus, when published, will be available on the website of materials or any of their contents. State. ////// Science for a better In relation to each member state of the European Economic Area which has implemented the Directive We do not accept any responsibility or liability for these policies and procedures. This announcement is an advertisement and does not, under any Sports, Successful I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. on for Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. R&D expenses before special items amounted to 5.3 billion euros. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Our innovative approach integrates foundational. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. 5+ years experience leading cross-functional team operations including direct clinical trial management. The following materials are not directed at or to be accessed by persons located in the United 2021 Jul 9;6(61):9792. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. To exercise your rights, you may contact us as at. in the United States absent registration or an applicable exemption from the registration We may update this Privacy Notice from time to time. Member State, except that an offer to the public in such Relevant Member State of any securities may